Pharmafile Logo

Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

- PMLiVE

As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.  

InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most: 

  • Which HCPs are showing early interest or unmet need? 
  • Where are we under- or over-investing across channels? 
  • How is our field and MSL activity likely to impact uptake? 
  • What indicators point to the strongest early launch opportunities? 

By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence. 

The full picture of commercial performance 

InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.  

Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action. 

“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.

“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.” 

A connected intelligence solution built for the pivotal pre-launch moment 

At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point: 

  • Omnichannel intelligence: More than 25M hours of HCP engagement data reveal where interest is building, which messages resonate, and which needs remain unmet. 
  • Field performance insight: Over 200 brand meeting analyses uncover how in-field activity shapes perception and influence, informing targeting and deployment strategy. 
  • Clinical foresight: U.S. and EU modeling of real-world evidence connects clinical signals to commercial outcomes – helping teams understand where market readiness is strongest. 
  • Predictive engagement: AI-driven models trained on longitudinal datasets forecast behavioral shifts, guiding investment toward the highest-impact channels and content. 

Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act. 

Leading the future of Intelligent Commercialization™ with InConcert™ 

By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™. 

  1. Proprietary data and infrastructure: Decades of integrated datasets spanning engagement, scientific, and commercial domains. 
  2. A connective AI backbone: A modular, LLM-powered platform that makes complex data easy to query, interpret, and operationalize. 
  3. Embedded expertise: Access to specialists from across Inizio – whose insights are both built into the models and available on demand – ensuring every interpretation is grounded in scientific and strategic rigor. 

Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows. 

“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke. 

“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.” 

With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches. 

Learn more about InConcert™ or get in touch with one of our experts today.

 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Living with: The journey from the patient’s perspective

View our re-vamped interactive infographic to unlock key insights from various Living With reports

Case study: How we iteratively tested and refined payer value messages

Find out how we helped our client to enrich their understanding of the value message trade-off choices and preferences made by payers

Video: Strategic engagement case study

Supporting the launch of a global vaccine with a programme of market research and strategic insights

Webcast: The virtual patient: How to use AI-powered conjoint to understand complex treatment decisions

Watch to find out how a combination of virtual patients and artificial intelligence can help you to better understand physicians’ decision making processes.

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Infographic: Therapy Watch Hyperlipidaemia

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Article: The rise of the healthcare influencer

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

Personalized Oncology: Calling for a New Kind of Partnership:

In the 1990s, biomarkers were the future of personalized medicine and a “lab on a chip” was the holy grail of understanding patient health. As much as past predictions of...

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

EVOKE STRENGTHENS LEADERSHIP TEAM IN EUROPE TO DELIVER MORE INTEGRATED CLIENT SOLUTIONS

*Corrina Safeio, promoted to Group Managing Director taking on responsibility for Evoke London and Evoke Mind+Matter *Lee Wales, promoted to Deputy Managing Director at Evoke Mind+Matter UK *Holly Ford, promoted...